ArticleBMC chemistry2025
Evaluation of antibacterial and antibiofilm efficacy of gentamicin-loaded solid lipid nanoparticles (GM-SLNs) against Acinetobacter baumannii infections.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections - an in vitro study.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii has become a notable "superbug" due to its rapid development of resistance to multiple classes of antibiotics. This study aimed to evaluate the antibacterial and antibiofilm effectiveness of gentamicin-loaded solid lipid nanoparticles (GM-SLNs) in treating infections caused by A. baumannii. Nanoparticles were synthesized using the double melt emulsion dispersion method. A. baumannii was isolated from wounds, blood, urine, and sputum through standard microbiological techniques. Antimicrobial susceptibility was tested using the Kirby-Bauer disk diffusion method. The biofilm-forming ability of A. baumannii isolates, the antibacterial activity of GM-SLNs, and the time killing assay were conducted following standard protocols with slight modifications. The impact of GM-SLNs on the expression of biofilm-related genes was analyzed using real-time PCR. A total of 37 A. baumannii strains were isolated from 41 clinical specimens. The most common antibiotic resistances were against gentamicin (GM), ciprofloxacin (CIP), ceftazidime (CAZ), and imipenem (IMP). 80% of the A. baumannii isolates were classified as multidrug-resistant (MDR). GM-SLNs reduced the minimum inhibitory concentrations (MICs) for all A. baumannii strains twofold, fourfold, and even up to eightfold compared to free GM. GM-SLNs were also significantly more effective than free GM in inhibiting biofilm formation in all A. baumannii isolates. Furthermore, the expression of the bap gene was significantly lower in all isolates treated with GM-SLNs compared to those treated with free GM. Overall, GM-SLNs represent a major breakthrough in the fight against A. baumannii and other biofilm-related infections, providing hope for more effective treatment options amid the growing challenge of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.